全文获取类型
收费全文 | 418篇 |
免费 | 13篇 |
国内免费 | 18篇 |
出版年
2023年 | 8篇 |
2021年 | 6篇 |
2020年 | 4篇 |
2019年 | 25篇 |
2018年 | 11篇 |
2017年 | 5篇 |
2016年 | 4篇 |
2015年 | 6篇 |
2014年 | 38篇 |
2013年 | 32篇 |
2012年 | 23篇 |
2011年 | 18篇 |
2010年 | 15篇 |
2009年 | 21篇 |
2008年 | 28篇 |
2007年 | 28篇 |
2006年 | 25篇 |
2005年 | 15篇 |
2004年 | 14篇 |
2003年 | 18篇 |
2002年 | 16篇 |
2001年 | 16篇 |
2000年 | 9篇 |
1999年 | 10篇 |
1998年 | 19篇 |
1997年 | 8篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 6篇 |
1993年 | 4篇 |
1992年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
排序方式: 共有449条查询结果,搜索用时 15 毫秒
11.
12.
13.
14.
Jennifer M. Davis Elizabeth Hyjek Aliya N. Husain Le Shen Jennifer Jones Lucia A. Schuger 《The journal of histochemistry and cytochemistry》2013,61(8):580-590
Pulmonary lymphangioleiomyomatosis (LAM) is a rare, low-grade neoplasm affecting almost exclusively women of childbearing age. LAM belongs to the family of perivascular epithelioid cell tumors, characterized by spindle and epithelioid cells with smooth muscle and melanocytic differentiation. LAM cells infiltrate the lungs, producing multiple, bilateral lesions rich in lymphatic channels and forming cysts, leading to respiratory insufficiency. Here we used antibodies against four lymphatic endothelial markers—podoplanin (detected by D2-40), prospero homeobox 1 (PROX1), vascular endothelial growth factor receptor 3 (VEGFR-3), and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)—to determine whether LAM cells show lymphatic differentiation. Twelve of 12 diagnostic biopsy specimens (early-stage LAM) and 19 of 19 explants (late-stage LAM) showed immunopositivity for D2-40 in most neoplastic cells. PROX1, VEGFR-3, and LYVE1 immunoreactivity varied from scarce in the early stage to abundant in the late stage. Lymphatic endothelial, smooth muscle, and melanocytic markers were partially co-localized. These findings indicate that lymphatic endothelial differentiation is a feature of LAM and provide evidence of a previously unidentified third lineage of differentiation in this neoplasm. This study has implications for the histological diagnosis of LAM, the origin of the neoplastic cells, and potential future treatment with drugs targeting lymphangiogenesis. 相似文献
15.
16.
17.
Hong‐Xia Yuan Xiu‐E Feng En‐Li Liu Rui Ge Yuan‐Lin Zhang Bao‐Guo Xiao Qing‐Shan Li 《Journal of cellular and molecular medicine》2019,23(1):453-463
Inflammation and reactive oxygen species (ROS) are important factors in the pathogenesis of atherosclerosis (AS). 5,2′‐dibromo‐2,4′,5′‐trihydroxydiphenylmethanone (TDD), possess anti‐atherogenic properties; however, its underlying mechanism of action remains unclear. Therefore, we sought to understand the therapeutic molecular mechanism of TDD in inflammatory response and oxidative stress in EA.hy926 cells. Microarray analysis revealed that the expression of homeobox containing 1 (HMBOX1) was dramatically upregulated in TDD‐treated EA.hy926 cells. According to the gene ontology (GO) analysis of microarray data, TDD significantly influenced the response to lipopolysaccharide (LPS); it suppressed the LPS‐induced adhesion of monocytes to EA.hy926 cells. Simultaneously, TDD dose‐dependently inhibited the production or expression of IL‐6, IL‐1β, MCP‐1, TNF‐α, VCAM‐1, ICAM‐1 and E‐selectin as well as ROS in LPS‐stimulated EA.hy926 cells. HMBOX1 knockdown using RNA interference attenuated the anti‐inflammatory and anti‐oxidative effects of TDD. Furthermore, TDD inhibited LPS‐induced NF‐κB and MAPK activation in EA.hy926 cells, but this effect was abolished by HMBOX1 knockdown. Overall, these results demonstrate that TDD activates HMBOX1, which is an inducible protective mechanism that inhibits LPS‐induced inflammation and ROS production in EA.hy926 cells by the subsequent inhibition of redox‐sensitive NF‐κB and MAPK activation. Our study suggested that TDD may be a potential novel agent for treating endothelial cells dysfunction in AS. 相似文献
18.
19.
20.